ThermoGenesis Corp. (NASDAQ:KOOL)

Managers are constantly diluting the stock distributing stock options as form of salary payment. More stock is being issued now.

Profitability is just around the corner, and 2 years worth of cash on hand just in case.

This stock has been a loser but is starting to get good press. Should see a bump up over next few months if it doesn't prove itself down it will go.

This stock is on the verge of showing a profit. The growth in sales is app. 34% from the same quarter of a yeaar ago. Prediction is current quarter will be 2 cets on the plus side.They have increased their distribution and now have distribution in the Asian part of the world. The growth potential is outstanding.

Has alway had great technology and intellectual property. Finally, after twelve years of unfulfilled promises, KOOL now has a first-class management team which is delivering. KOOL is finally profitable and growing revenue and profit margins. Just announced a major deal to enter China and Hong Kong markets.

A moderately conservative way to play the risky stem cell sector. Projected for positve EPS in next year and would be low PE if hits estimate.

Good company with products having greater and greater demand.

MACD and price channels both show bearish levels for years to come.

With the stock trading near its 52-week low and some solid products and a GE partnership coming down the pipeline, I think the future is bright for this stock. Super value.

This could be huge.

Good technologies worth a lot if management can get its act together.

@ 2.50 I can do math easily and fantasize all day, lets see if we can get a rally first.

I may have entered KOOL at the wrong price in CAPS, but KOOL is looking cool to this RL investor at this price. Catalysts are imminent (summer 2007).

That said, a company that cannot produce its product in sufficient quantity to meet market demand is almost as bad as a company that produces a product that it cannot market or that the market does not want. Hence the sell-off. In this case, I think KOOL was oversold.

Good partnerships (GE), good business model (disposables), good technology, sexy sector (health care, diagnostics, stem cells).

Here's a cut and paste that will help me remember what I was thinking (6/28/07) when I added KOOL to my RL portfolio.

"Both ThermoGenesis (KOOL - Cramer's Take - Stockpickr - Rating) and ViaCell (VIAC - Cramer's Take - Stockpickr - Rating) offer storage systems for stem cells extracted from umbilical cords and held for future use. But Brozak feels that ThermoGenesis operates under a far more attractive business model.

GE Healthcare, an industry heavyweight with real marketing clout, began selling ThermoGenesis' AutoXpress cord blood processing system more than a year ago. Calls for disposable bags used by the AXP system -- a key driver of ThermoGenesis' revenue growth -- have exploded since that time. Indeed, the company suffered a disappointing setback earlier this year as it struggled to ramp up its production efforts.

"The demand [for disposables] is right now considerably exceeding our supply," ThermoGenesis CEO Philip Coelho told investors back in February. Still, "we think when the GE sales force sees the supply matching the demand -- and going above it -- then they will not have trouble finding additional orders."

ThermoGenesis last month went on to report record quarterly revenue, with sales of disposables rocketing 140% as the company worked to address its production problems. But the company's stock has nevertheless suffered in recent weeks, due in part to its removal from the Russell 3000 index. The shares, down 6 cents to $2.45 Friday, currently trade near the bottom of their 52-week range.

Has great demand and is one of the only stem cell stocks that will make a profit within the next year.

This company will be profitable very soon, and I don't see why this stock won't jump within a year or two.

it is partnered with GE and other big wigs. It dropped on not meeting their demand

industry leader with unique products for which demand will increase

No matter who wins the "stem cell supply war" this company manufactures the device in which they will be stored. Income generated from both the machines and the residules (bags, cleaning supplies, maintenance contracts) makes each sale worth many $$$. Should perform better than most pix made by the fool.

stem cells are kool.